Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ACIPHEX

« Back to Dashboard

Aciphex is a drug marketed by Eisai Inc and is included in two NDAs. It is available from seven suppliers. There is one patent protecting this drug.

The generic ingredient in ACIPHEX is rabeprazole sodium. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

Summary for Tradename: ACIPHEX

Patents:1
Applicants:1
NDAs:2
Suppliers: see list7
2013 Sales:$683,359,000

Pharmacology for Tradename: ACIPHEX

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors

Clinical Trials for: ACIPHEX

Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
Status: Recruiting Condition: Nonvariceal Upper Gastrointestinal Bleeding

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Status: Completed Condition: Heartburn

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Status: Completed Condition: Heartburn

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers
Status: Terminated Condition: Peptic Ulcer Hemorrhage

A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury
Status: Active, not recruiting Condition: Osteoarthritis; Arthritis, Rheumatoid; Dyspepsia

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
Status: Completed Condition: Gastroesophageal Reflux

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection
Status: Completed Condition: Early Gastric Adenocarcinoma; Adenocarcinoma, Tubular

A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers
Status: Completed Condition: Healthy

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
Status: Completed Condition: Gastroesophageal Reflux

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Status: Recruiting Condition: Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
ACIPHEX SPRINKLE
rabeprazole sodium
CAPSULE, DELAYED RELEASE;ORAL204736Mar 26, 2013RXNo<disabled><disabled>
Eisai Inc
ACIPHEX
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973May 29, 2002DISCNNo5,045,552*PED<disabled><disabled>
Eisai Inc
ACIPHEX SPRINKLE
rabeprazole sodium
CAPSULE, DELAYED RELEASE;ORAL204736Mar 26, 2013RXYes<disabled><disabled>
Eisai Inc
ACIPHEX SPRINKLE
rabeprazole sodium
CAPSULE, DELAYED RELEASE;ORAL204736Mar 26, 2013RXYes5,045,552*PED<disabled><disabled>
Eisai Inc
ACIPHEX SPRINKLE
rabeprazole sodium
CAPSULE, DELAYED RELEASE;ORAL204736Mar 26, 2013RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc